Terms: = Ovarian cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Treatment
17 results:
1. High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
Brzezinska B; Mysona DP; Richardson KP; Rungruang B; Hopkins D; Bearden G; Higgins R; Johnson M; Satter KB; McIndoe R; Ghamande S; Purohit S
Gynecol Oncol; 2023 Dec; 179():1-8. PubMed ID: 37862814
[TBL] [Abstract] [Full Text] [Related]
2. [Mechanism of Marsdenia tenacissima against ovarian cancer based on network pharmacology and experimental verification].
Hu YJ; Wei LY; Zhao J; Zhu QF; Meng ZY; Meng JJ; Chen JJ; Xu LY; Zhou YY; Han YL
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2222-2232. PubMed ID: 37282910
[TBL] [Abstract] [Full Text] [Related]
3. [Molecular mechanism of Spatholobi Caulis in treatment of ovarian cancer based on network pharmacology and experimental verification].
Zhu SC; Cai J; Wu CY; Cheng CS
Zhongguo Zhong Yao Za Zhi; 2022 Feb; 47(3):786-795. PubMed ID: 35178962
[TBL] [Abstract] [Full Text] [Related]
4. A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer.
Beachler DC; Lamy FX; Russo L; Taylor DH; Dinh J; Yin R; Jamal-Allial A; Dychter S; Lanes S; Verpillat P
J Ovarian Res; 2020 Aug; 13(1):101. PubMed ID: 32867806
[TBL] [Abstract] [Full Text] [Related]
5. Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis.
Assis J; Pereira C; Nogueira A; Pereira D; Carreira R; Medeiros R
Cancer Treat Rev; 2017 Dec; 61():35-52. PubMed ID: 29100168
[TBL] [Abstract] [Full Text] [Related]
6. Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities.
Li L; Bai H; Yang J; Cao D; Shen K
Oncotarget; 2017 Feb; 8(9):15136-15148. PubMed ID: 28122348
[TBL] [Abstract] [Full Text] [Related]
7. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ercc2.
Zhao H; Yu X; Ding Y; Zhao J; Wang G; Wu X; Jiang J; Peng C; Guo GZ; Cui S
Oncotarget; 2016 Aug; 7(33):53254-53268. PubMed ID: 27449101
[TBL] [Abstract] [Full Text] [Related]
8. Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
Di Francia R; De Lucia L; Di Paolo M; Di Martino S; Del Pup L; De Monaco A; Lleshi A; Berretta M
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4443-54. PubMed ID: 26636535
[TBL] [Abstract] [Full Text] [Related]
9. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y
Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, xpd and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract] [Full Text] [Related]
11. Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.
Arienti C; Tesei A; Verdecchia GM; Framarini M; Virzì S; Grassi A; Scarpi E; Turci L; Silvestrini R; Amadori D; Zoli W
J Transl Med; 2011 Jun; 9():94. PubMed ID: 21689426
[TBL] [Abstract] [Full Text] [Related]
12. 'Genetic profiling' and ovarian cancer therapy (review).
Vella N; Aiello M; Russo AE; Scalisi A; Spandidos DA; Toffoli G; Sorio R; Libra M; Stivala F
Mol Med Rep; 2011; 4(5):771-7. PubMed ID: 21687948
[TBL] [Abstract] [Full Text] [Related]
13. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.
Khrunin AV; Moisseev A; Gorbunova V; Limborska S
Pharmacogenomics J; 2010 Feb; 10(1):54-61. PubMed ID: 19786980
[TBL] [Abstract] [Full Text] [Related]
14. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
[TBL] [Abstract] [Full Text] [Related]
15. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract] [Full Text] [Related]
16. Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
Gornati D; Zaffaroni N; Villa R; De Marco C; Silvestrini R
Anticancer Drugs; 1997 Jun; 8(5):509-16. PubMed ID: 9215615
[TBL] [Abstract] [Full Text] [Related]
17. ERCC1 and ercc2 expression in malignant tissues from ovarian cancer patients.
Dabholkar M; Bostick-Bruton F; Weber C; Bohr VA; Egwuagu C; Reed E
J Natl Cancer Inst; 1992 Oct; 84(19):1512-7. PubMed ID: 1433335
[TBL] [Abstract] [Full Text] [Related]
